Upload
pramila-s-das
View
80
Download
8
Embed Size (px)
Citation preview
A Danish-Swedish Life Science Cluster
Medicon ValleyA Danish-Swedish Life Science Cluster Located in the Øresund Region
© Medicon Valley Alliance 2007Photos: Brigdephoto, Copenhagen Capacity, Medicon Valley Alliance, NeuroSearch and VisitDenmark
Contents04 Prologue
06 Chapter 1 | Welcome to Medicon Valley • Get more information
09 Chapter 2 | Business Environment • Strongholds • A growing industry • International attention • A mature pipeline • Continuous growth and success • Business is easy • Lean business • Productive work culture
14 Chapter 3 | Science Base • Funding • International ranking • Centres of Excellence • Medicines research academy
18 Chapter 4 | Access to Talent • Reseachers and life science specialists • Management expertise • High mobility • Language skills • Academic resources • The Øresund University
23 Chapter 5 | Access to Capital • Local investors • International investors present in Medicon Valley • International exposure of local companies • Looking ahead
26 Chapter 6 | Support Structure • Tech transfer organisations and incubators • Full service science • A comprehensive population registration system • An exceptional place to develop personalised medicine • Registration and certifi cation of medicine and medical devices • Contract research and manufacturing organisations of a high standard
32 Chapter 7 | Infrastructure • Medicon Valley – a new Scandinavian base
34 Chapter 8 | Quality of Life • Advanced lifestyle • A perfect balance • Vibrant culture • Close to nature
39 Chapter 9 | Point of Entries • Medicon Valley Alliance • Copenhagen Capacity • Region Skåne
”Add to that a comprehensive social services network, a safe society where everyone
speaks English and carefully planned cities with easy commuting, and the Scandinavian
biotech industry appears to offer an unbeatable combination.”
NewScientist, 5 May 2007
Medicon Valley is a bi-national cluster that spans
the island of Zeeland in eastern Denmark and
the Skåne region of southern Sweden.
Medicon Valley is one of Europe’s strongest life
science clusters with a large number of life
science companies located within a very small
geographical area. Local and international in-
vestors have provided the capital needed for
the continued growth of these companies. To-
gether with specialised service providers such
as different CROs, CMOs, consultants and patent
attorneys, all the competences required to bring
new and innovative products to the market are
available.
In Medicon Valley you will fi nd a unique interplay
between businesses, hospitals, universities and
public research institutions – a successful prac-
tise of the triple helix model. Based on this model,
interaction and network activities take place
among the various public and private life science
players. This interaction results in a dynamic en-
vironment rich in innovation and knowledge sha-
ring – prerequisites for new company formation
and growth of the cluster.
Welcome to Medicon Valley
These unique conditions have led Medicon Valley
to foster one of the most impressive pipelines
within commercially attractive therapeutic areas,
such as diabetes, neuroscience, infl ammation, in-
fectious diseases and cancer.
There are many good reasons why the world is
taking a close look at Medicon Valley.
GET MORE INFORMATION
To investigate the opportunities in Medicon
Valley further, feel free to contact the point of
entries listed below. Contact information is pla-
ced at the back of the brochure.
• The cluster organisation Medicon Valley
Alliance – if you wish to attain information
about life science in Medicon Valley and
contact information on the public and pri-
vate players.
• The investment promotion agencies Copen-
hagen Capacity (Denmark) and Region Skåne
(Sweden) – if you are interested in knowing
more about business opportunities or are
looking to invest in Medicon Valley.
Page 6 | Chapter 1 | Welcome to Medicon Valley
The Medicon Valley Ambassador Programme
No cluster can sustain growth in isolation. Life science technologies, investment opportunities
and research collaborations are all global in their perspectives and the future belongs to clus-
ters that can enter into productive win-win relations with other growing regions. That is why
Medicon Valley Alliance has recently developed a strategic globalisation initiative, called the
Medicon Valley Ambassador Programme. This initiative involves the establishment of close
strategic ties between important life science clusters around the globe with exchanges of
life science ambassadors. The ambassadors will work together to develop win-win opportuni-
ties between clusters by scouting for science and business opportunities and by enhancing
networking between the participating clusters. Get more information at www.mva.org.
The Region
Medicon Valley lies in the Danish-Swedish Øresund Region, which consists of Zeeland and Skåne and
covers a total of 21,000 km². It is the new regional centre of northern Europe with the Danish
capital Copenhagen as the pivotal point.
The Øresund Region has a large number of advantages:
• The largest metropolitan area in Scandinavia
• Great access to the Scandinavian, North European and Baltic markets
• Regional proximity and short distances
• Well-developed infrastructure
• Very good language skills
• Excellent quality of life
Cluster Facts
• Population of approx. 3.5 million
• Companies with R&D and/or production: Approx. 100 (red) biotech companies, 25 pharma
companies (7 major) and 100 medtech companies
• International companies with affiliates in Medicon Valley: More than 200 pharma companies
and 170 medtech companies
• Approx. 40,000 employees in the private life science sector
• Approx. 10,000 life science researchers in the private and public life science sector
• 12 universities, 5 of which supply life science related educations
• Approx. 150,000 students, 45,000 of whom study life science
• Approx. 2,600 life science PhD students are enrolled at the universities of Copenhagen and Lund
• Approx. 7,000 life science university students graduate every year
• 32 hospitals, 11 of which are university hospitals
• 6 science parks with a significant focus on life science
• 6 incubators, 2 of which have a significant focus on life science
• More than 50 contract research organisations and contract manufacturing organisations
Page 7 | Chapter 1 | Welcome to Medicon Valley
The Vision for Medicon Valley
Medicon Valley will be among the fi ve most
attractive bioregions worldwide, recognised
for:
• An excellent scientifi c environment and
pool of talent
• Outstanding access to knowledge sha-
ring and technology transfer between
universities, hospitals and industry
• An innovative and entrepreneurial environ-
ment, with competitive enterprises
• A truly international perspective and glo-
bal network
STRONGHOLDS
The major pharmaceutical corporations found in
Medicon Valley – Novo Nordisk, AstraZeneca, LEO
Pharma, H. Lundbeck, Nycomed, Ferring Pharma-
ceuticals and ALK-Abelló – constitute the back-
bone in what has become Europe’s most densely
packed life science cluster. Based on a long
research commitment, the cluster holds core
competences in therapeutic areas like diabetes/
metabolism, neuroscience, cancer, infl ammation
and allergy. Furthermore, Medicon Valley is in the
forefront of personalised medicine.
A GROWING INDUSTRY
Biotech is one of the fastest growing industries
within life sciences. The majority of the region’s
more than a hundred biotech companies has
emerged since the mid-1990s. Many new com-
panies have managed to bring their research
forward into the clinical stages of development.
The sustained growth and maturing of these
companies is being secured by a constant injec-
tion of mostly international venture capital to
the region. In 2006, this amounted to more than
EUR 700 million and ensured Denmark ranked as
the number one nation in Europe as measured
by the amount of private capital invested as a
percentage of gross domestic product (Nature
Biotechnology, Dec. 2006).
INTERNATIONAL ATTENTION
Biotech companies in Medicon Valley have suc-
ceeded in making an impact on the international
scene. In December 2006, Genmab and Glaxo-
SmithKline closed the largest ever global biotech
licence agreement with a potential value of EUR
1.5 billion. In January 2007, BioInvent entered a
EUR 135 million co-development agreement with
Genentech to develop and commercialise Bio-
Invent’s proprietary antibody candidate drug for
the US market. In spring 2007, Bavarian Nordic
closed a EUR 1.2 billion deal to deliver smallpox
vaccines to the US Department of Health and
Human Services. In addition, Active Biotech has
signed several agreements with international
partners within the areas of autoimmune disea-
ses and transplant rejection.
Business Environment
Medicon Valley is characterised by a healthy busi-
ness environment with extensive collaboration
between life science companies, academic resear-
chers and clinicians. It is very easy to establish
new companies in the region and a tangible result
has been the occurrence of a signifi cant number
of new and growing life science companies both
within red biotech and medical technology. This
development has led to a substantial growth in
the number of employees and put together the
life science industry in Denmark and Sweden now
ranks second in the world, behind the US (Nature
Biotechnology, Jan. 2007).
”The level of innovation in Medicon Valley is high, which in combination with
a fl ourishing VC market and simple regulations, makes the conditions unique for business development.”
Bo-Ragnar TolfManaging Director
ACADIA Pharmaceuticals(Malmö, Sweden)
Page 9 | Chapter 2 | Business Environment
A MATURE PIPELINE
From the modest beginnings a decade or so ago,
Medicon Valley has advanced into an establis-
hed life science cluster consisting of companies
with a wide range of candidates in their re-
spective pipelines.
More biotech companies than ever have pro-
jects in clinical trials and in total, products tar-
geted towards almost 200 different indications
are present in the different phases of clinical
development. Leaving out big pharma companies,
close to 150 new indications are under clinical
investigation by the smaller biotech companies.
Around 70% of all clinical indications under inve-
stigation fall within the four therapeutic areas
where Medicon Valley has secured its internatio-
nal reputation. While the big pharma companies
”If you want access to fi rst-class research conditions,
come to Medicon Valley.” Bertil Lindmark
Global Vice PresidentAstraZeneca (Lund, Sweden)
are predominantly involved in research within
their traditional therapeutic areas, biotech com-
panies play a role in all therapeutic areas, but
have their most signifi cant contribution within
cancer research and immunology.
The strength and research intensity of the Medi-
con Valley cluster is illustrated by the region’s
drug development pipeline which is comparable
both quantitatively and qualitatively with the
output produced by geographically larger areas
in Europe.
Total pipeline 2006Therapeutic indications Incl. big pharma
Page 10 | Chapter 2 | Business Environment
Pipeline 2006Therapeutic indications Only biotech
CONTINUOUS GROWTH AND SUCCESS
The positive development in Medicon Valley is
expected to continue in the years to come. The
optimism in the region is apparent from the fact
that more than ten biotech companies expect
to go public in 2008-2010. The extensive pipe-
line of new products will continue to develop and
eventually lead to the launch and marketing of
many new and better therapeutic agents. More
companies will generate revenue and more com-
panies will be founded by a new generation of
entrepreneurs thanks to the availability of risk
willing capital.
Another positive sign that indicates a conti-
nuous growth is the expansion and building of
new science parks and incubators in Medicon
Valley. During 2007 the Lund Bioincubator ope-
ned, and in less than 2 years another science
park with incubator, COBIS, is to be opened clo-
se to Copenhagen Biocenter.
BUSINESS IS EASY
Medicon Valley constitutes a business friendly
region, and in particular for R&D intensive com-
panies. Corporate taxation rates are among the
lowest in Europe and effi cient and digitalised
government procedures means that companies
are able to reduce their administrative costs
and allocate resources to core activities.
Setting up and operating a business in Medicon
Valley is surprisingly easy. The public sector
boasts world-class quality while managing to
operate both quickly and effi ciently. The level
of regulation imposed on start-ups in Denmark
and Sweden is minimal, and this means the area
offers some of the easiest, fastest and chea-
pest start-up procedures to be found anywhere
– as reported by the World Bank.
A survey from the internationally acknowledged
Institute for Management Development (IMD)
shows that Danish and Swedish bureaucracy is
very low, and bribery and corruption is virtually
non-existent. Furthermore, the legal environment
is such that it does not restrain R&D activities.
In Medicon Valley, public authorities work with
companies, not against them.
LEAN BUSINESS
Lean is a way of life in Medicon Valley that busi-
nesses benefi t from. In few other places is it
so easy to interact with government services.
Regulation is kept to a minimum and is based on
trust and self-regulation rather than strict re-
gulatory controls. The quality of public services
is at its highest level and means corporations
are relieved of social security burdens.
The labour market in Sweden and Denmark is to a
large extent built on the collective agreements
between unions and employers. It is relatively
simple to employ and give notice to employees
in Sweden and Denmark – certainly compared
with much of Europe. The fl exicurity model with
liberal hiring-and-fi ring rules, combined with a
high level of social security plays an important
role, especially in Denmark. It enables companies
to quickly adapt to market changes.
PRODUCTIVE WORK CULTURE
The working environment in Medicon Valley is
attractive to companies seeking employees who
can take responsibility and work in teams that
transcend traditional functions. The work cul-
ture is a rare mix of lean, effi cient work styles
galvanised by a constant strive for new ideas
to improve business processes. Many foreign
companies have found that this work culture
facilitates higher productivity levels and better
results. The work culture leaves room for infl u-
ence and responsibility. As a result, employees
stand out as the most satisfi ed and motivated
in international rankings.
”The proximity and mobility of high quality labour in the region allows us to stay innovative.”Kurt Erling BirkPresident and Chief Executive Offi cerAmbu (Ballerup, Denmark)
Page 11 | Chapter 2 | Business Environment
”It is a pleasure working with the creative Scandinavians who seem to be reinventing not just biotech, but the very way business is done. I see
this as the makings of a competitive hub for innovative companies, entrepreneurs and technologies in the very near future.”
Ishan GuptaHead of Sales & Marketing
ViroGates (Lyngby, Denmark)
���������� ��������� �����������������
������������
��������������������������������������������������
���������������������������������������������������������
���������������������������������������������������������
��������������������������������������������������������
�������������������������������������������������������
�������������������������������������������������������������
��������������������������������������������������
�������������������������������������������������
Science Base
”The science base here is excellent and this goes for several therapeutic fi elds.
Within diabetes in particular, Medicon Valley is undoubtedly a global hotspot.”
Mads Krogsgaard ThomsenExecutive Vice President and Chief Science Offi cer
Novo Nordisk (Bagsværd, Denmark)
Page 14 | Chapter 3 | Science Base
The two largest universities in Scandinavia are
Lund University (LU) and the University of Copen-
hagen (UC) in Medicon Valley. Together with the
other universities that have life science edu-
cations (Danish Technical University (DTU) and the
universities in Malmö and Roskilde), they house
45,000 life science students.
FUNDING
In Medicon Valley, both private and public R&D
spending is ample. Health-related biotechnology
and life sciences are strategic focus areas in
Denmark and Sweden. Primary funding comes
from the Danish Ministry for Science, Technology
and Development, the Swedish Research Council,
the Swedish Strategic Research Foundation
and the Swedish Governmental Agency for Inno-
vation Systems (VINNOVA).
Although Sweden is already spending more than
3% of GDP on research (3.7% compared to 2.6%
in Denmark), public research spending is below 1%
in both countries. Both governments are dedi-
cated to increase their part.
Private foundations provide signifi cant contri-
butions to public research. The Knut and Alice
Wallenberg Foundation (KAW Foundation) is the
most important private contributor to infra-
structure in Sweden, whereas the Novo and
Lundbeck foundations play an equally important
role in Denmark.
INTERNATIONAL RANKING
The University of Copenhagen and Lund Univer-
sity are both ranked among the hundred best
universities in the world of 500 ranked univer-
sities. In fact, the University of Copenhagen is
ranked the best in Scandinavia and number 8 in
Europe (Shanghai Jiao Tong, 2007).
A recent bibliometric study ranked Denmark and
Sweden as numbers 3 and 5 respectively, after
the US and Switzerland at the top (Veten-
skapsrådets rapportserie 13: 2006). About half
of all publications from the region are within
medicine and 25% within related sciences (The
Øresund Science Region: a cross-border part-
nership between Denmark and Sweden, OECD,
2006).
RESEARCH INFRASTRUCTURE
Medicon Valley universities are supporting re-
search of the very highest international stan-
dard and the focus on biotechnology and medi-
cine has created several brand new research
centres.
One such is BMC, the Biomedical Center at LU.
This has been gradually enlarged to host 110
research groups with 800 scientists, working
within immunology, tumour immunology, con-
nective tissue research, molecular signalling,
molecular biology, developmental biology, and
neuroscience and cell biology. The latest addi-
tion from 2006 includes Lund Bio-Incubator with
about ten start-up companies.
CRC, the Clinical Research Centre in Malmö,
houses 400 researchers specifi cally engaged
in diabetes, blood & defence, and public health
research.
Copenhagen Biocenter contains state-of-the-art
laboratories, including animal research facilities
for cancer research, bioinformatics, proteo-
mics and crystallography. The Biocenter houses
among others the BRIC (Biotech Research and
Innovation Centre) research groups. A bio-incu-
bator, COBIS, is being constructed close to the
biocenter and will open in 2009.
The Swedish national research unit MAX-lab in
Lund is due for a major upgrading to MAX 4. It is a
synchrotron radiation laboratory, where e.g. cell
consitutents and biomolecules are studied.
”For academic research, the pos-sibilities for innovative partners in
this region are outstanding.”Bo Ahrén
Head of Medical FacultyLund University (Lund, Sweden)
Page 15 | Chapter 3 | Science Base
MEDICINES RESEARCH ACADEMY
The Medicines Research Academy in Copenhagen
will encompass all pharmaceutical disciplines from
early discovery to clinical development, and manu-
facturing. This institution is in a partnership with
industry and the regulatory authorities and also
has links to the research school for Medicines
Development at LU.
Details on public and private research are pre-
sented below in fact boxes for the following fi ve
Areas of Excellence:
• Neuroscience
• Cancer
• Infl ammation, Allergy and Autoimmune Diseases
• Diabetes and Metabolic Diseases
• Infectious Diseases
ESS, the European Spallation Source, might be
hosted in Lund close to MAX-lab from 2017 to
allow advanced neutron scattering research on
the properties of materials and molecules. When
implemented, another 5,000-6,000 researchers
are expected to work in the region.
CENTRES OF EXCELLENCE
Medicon Valley holds a number of Centres of Ex-
cellence. These include centres for nanotechno-
logy and stem cell biology (LU), for bioinformatics
and microbial biotechnology (DTU), for compara-
tive genomics, and epigenetics (UC). The sizes
of the universities make it possible to promote
interdisciplinary research such as neuroscience,
functional food (LU) and drug discovery (UC).
Neuroscience
Public NeuroLund is a program to explore mechanisms of neurodegeneration in cell and animal
models of Parkinson’s, Huntington’s and Alzheimer’s diseases, stroke, epilepsy, depression and
bipolar disorder. NeuroFortis at the Wallenberg Neuroscience Center is a joint effort between
four strong research teams in the fi eld of brain damage and repair, and a pioneering research
group on human embryonic stem cells. UC supports a neuro cluster of nearly 50 senior scientists,
to promote faculty-spanning research projects. It has focus on neuro-degeneration, neuronal
signalling, biological psychiatry, motor control & rehabilitation, imaging and genomics/proteomics.
Private Lundbeck continues developing new anti-depressive drugs and treatments for schizophrenia,
Alzheimer’s and Parkinson’s disease. A number of biotech companies work on proprietary technology
platforms. Examples include Neurosearch (ion channels and transporters), Acadia (G-protein coupled
receptors), Enkam (neuronal cell adhesion molecules), NS Gene (encapsulated cell bio-delivery), Phar-
mexa (immunotherapy), Neuropharma (brain protective substances), Exini Diagnostics, Schizo-
Detect (diagnostic decision support) and QuickCool (rapid brain cooling devices).
Page 16 | Chapter 3 | Science Base
Cancer
Public More than ten research groups at BRIC are con-
centrating on oncology and cancer, with the aim to
understand the molecular mechanisms behind the
disease(s). The Danish Cancer Society funds frontline
research in oncology. Create Health is a Centre of
Excellence for translational clinical cancer research
in Lund. The eight research groups, working from
patient samples via preclinical research and tech-
nology development and back to the clinic, aim at fi nding
and applying biomarkers to the diagnoses and treatment
of the individual patient.
Private Several biotech companies are utilizing their
proprietary technology platforms for developing new
cancer treatments. Examples include BioInvent, Gen-
mab, Pharmexa, Symphogen (antibodies), Santaris Phar-
ma (RNA analogues), Nordic Vaccine, Meabco (metal
ions, small molecules developed against new targets),
Active Biotech, Topotarget (small molecules against
new targets) , SpectraCure (photodynamic dosing),
Dako (diagnostics), DanDrit (dendritic cells) and Zgene
(gene diagnostics).
Infl ammation, Allergy and Autoimmune Diseases
Public CCI, Copenhagen Cluster of Immunology with near-
ly 50 senior scientists, focuses on how immune respon-
ses are induced, selected and regulated. The cluster
is linked to the Graduate School of Immunology. IIR,
Institute for Infl ammation Research in Copenhagen,
performs investigations of immunogenicity and aller-
genicity of polypeptides, and monitor (auto) antibody
development in patients receiving biologics. Chip (Chro-
nic infl ammation program), TIM (tissues in motion) and
Blood and defence are major collaborative projects at
Lund University for research on basic mechanisms in
clinical disease, where key components are shared bet-
ween disease such as rheumatoid arthritis, systemic
lupus erythematosus, allergy and MS (multiple sclerosis).
Private AstraZeneca’s research unit focuses on res-
piratory diseases as well as infl ammatory diseases such
as rheumatoid arthritis and osteoarthritis. Other phar-
maceutical and biotech companies develop treatments
for various diseases, e.g. AstraZeneca, Resistentia
(respiratory tract infl ammations), Genmab, Ferring,
Cartela (arthritis) , Active Biotech (MS) , BioInvent
(atherosclerosis), Resistentia (respiratory diseases),
Astion Pharma, Valderm (psoriasis) , AnaMar, Euro-
Diagnostica (diagnostics), Hansa Medical (transplant
rejection), Alsensa, Atonomics, Curalogic, Refl ab and
Chemotechnique Diagnostics (allergy). ALK-Abelló re-
cently launched the fi rst oral vaccine against grass
pollen.
Diabetes and Metabolic Diseases
Public LUDC, Lund University Diabetes Center, performs
research from the fundamental cell biology of insulin-
producing and insulin-responsive cells to the everyday
clinical problems of metabolic control and late-com-
plications. The Antidiabetic Food Centre in Lund is an
inter-disciplinary collaboration between 40 research lea-
ders with the aim to fi nd a basis for the design of func-
tional foods, i.e. food which lowers the risk factors for
obesity, type 2-diabetes and cardiovascular diseases.
UC has several research groups engaged in basic and
applied research within all aspects of both type 1 and
type 2-diabetes.
Private The presence of Novo Nordisk makes Medicon
Valley’s diabetes research broad and deep, covering the
entire fi eld from molecular research to epidemiology.
Steno Diabetes Center is a diabetes research hospi-
tal and international teaching centre, owned by Novo
Nordisk and private-publicly fi nanced by Novo Nordisk
and the Capital Region of Copenhagen. The Hagedorn
Research Institute is an independent basic research
component of Novo Nordisk. It focuses on curing dia-
betes by preserving or reconstituting functional beta-
cell mass. Several Medicon Valley biotech companies are
developing treatments based on proprietary technology
platforms — these include Zealand Pharma (peptides for
T2D), 7TM Pharma (G-protein coupled receptors) and
Rheoscience (in vivo models). ØDA, Øresund Diabetes
Academy, is a cross-regional and cross-sectoral interest
group managed by Medicon Valley Alliance. ØDA fi nances
several PhD scholarships and an annual Diabetes Day.
Infectious Diseases
Public SSI, Statens Serum Institut, controls the diagno-
sis and treatment of infectious diseases and biological
threats. It has a long standing commitment to research
and works with infectious agents, resistant bacteria
and different vaccines. Copenhagen’s CISU, Interna-
tional Health, performs research on drug resistance
and drug development for malaria, tuberculosis and
HIV/AIDS. Immunological Bioinformatics at DTU Cen-
ter for Biological Sequence Analysis has a simulation
model of the human immune system and a database
with all human pathogens, to identify epitopes aiding
the search for new vaccines and therapies. LU has inter-
nationally recognised research groups working with
mechanisms behind bacterial infections. Malmö Uni-
versity Hospital is a WHO global reference laboratory
for diagnostics of Papilloma virus.
Private Several biotech companies work with diagno-
sing, preventing or treating infectious diseases, e.g.
Bavarian Nordic, Pharmexa, Glycom (vaccines), Maxygen,
NatImmune (protein-based therapeutics), Symphogen
(antibodies), Dermagen, LICA Pharmaceuticals, Neobio-
tics (novel anti-microbial peptides and small molecu-
les), and Virogates (diagnostics).
Life science is a very exciting industry, since it
calls for a wide specialisation of the workforce
Many different disciplines are required to bring
new ideas through the different stages, from
discovery through preclinical and clinical develop-
ment, to manufacturing and marketing. New and
emerging technologies offer great opportunities
to challenge unmet medical needs, but the imple-
mentation must be balanced against changing
and often mounting regulatory requirements and
constraints. The complexity is increased even
further by the existence of many different the-
rapeutic areas, adding specifi c requirements for
effi cacy documentation.
One of the highlighted advantages of a life science
region like Medicon Valley is that the clustering
of universities, hospitals, large international and
R&D based pharma and medtech companies, and
hundreds of small and medium enterprises (SMEs),
facilitates technology transfer and access to a
signifi cant pool of talent.
RESEARCHERS AND LIFE
SCIENCE SPECIALISTS
Medicon Valley combines quality and quantity of
life sciences. The number of bio/medical publica-
tions is very high, on average 3,200 per year and
includes a large number of clinical articles, indi-
cating a vivid development of new medicines in
the region. The total is considerably higher for
example, than from the universities of Oxford
(England) or Stanford (US), and slightly higher
than from Karolinska Institutet (Sweden) (Grant
Lewison, 2004).
About 40,000 people are employed in the pri-
vate life science sector in Medicon Valley. The
region houses the global headquarters of the
fi ve international pharma and medtech compa-
nies, Novo Nordisk, H. Lundbeck, Leo Pharma,
Coloplast and Ambu. There is also a signifi cant
R&D site for AstraZeneca and major research
or production units for Ferring Pharmaceuticals,
Nycomed, McNeal, and Gambro. Together these
large companies have more than 6,000 scientists
employed. All the vital competencies needed to
attract qualifi ed life science talent can be found
among the remaining 200 biotechnology and
medical device companies conducting R&D in
Medicon Valley. Vital competencies are also pro-
vided by the more than 50 different service
providers in preclinical or clinical development,
IPRs, regulatory affairs and contract manufac-
turing fi rms. The excellent clinical development
profi le and facilities have attracted an increasing
number of international companies and activities
to the region.
MANAGEMENT EXPERTISE
Over the last decade more than a hundred new
biotech companies have been founded in Medicon
Valley. They have matured and a signifi cant propor-
tion of these are now in late clinical development
stage and close to market approval for their
fi rst products. Many companies have already left
the venture capital phase and are now listed on
the Nordic OMX stock exchange or other smaller
listings. These experiences mean that many exe-
cutives have hands-on know-how about all critical
facets of entrepreneurship, IPOs and sustainable
business generation.
”Our decision to locate in Medicon Valley was very
signifi cantly infl uenced by the quality of the work-
force in the region – it is exceptionally high and
fl exible.”Paul Coleman
CEO, Vice President for Government Affairs-International
Biogen Idec
Access to Talent
Percentage of population speaking English
Source: Eurobarometer, European Commission, February 2006
Page 18 | Chapter 4 | Access to Talent
”Our success depends on attracting talent. With a
location in Medicon Valley, we have access to a fi rst-
class pool of scientists and professionals.”
Claus BræstrupPresident and Chief
Executive Offi cerLundbeck (Valby, Denmark)
University of Copenhagen has strengthened its
life science position even further after the mer-
ger in 2007 with the Royal Veterinary and Agri-
cultural University and The Danish University of
Pharmaceutical Sciences. This resulted in adding
the new faculties of Life Sciences and of Pharma-
ceutical Sciences, respectively. More than 1,200
life science PhD students are enrolled at Uni-
versity of Copenhagen.
Lund University educates life science students
at the faculties of medicine, natural sciences,
and technology (Lund University of Technology).
These faculties offer many educational program-
mes, including biochemistry, biophysics, biotech-
nology, biomedicine, medicine and nursing, and
also include the two university hospitals in Malmö
and Lund. About 1,400 life science PhD students
are enrolled at Lund University together with
approx. 900 life science researchers. The under-
graduate and postgraduate programmes, to-
gether with the extensive international student
exchange programmes, secure a steady fl ow of
new and highly qualifi ed researchers both for the
private companies and the universities.
THE ØRESUND UNIVERSITY
The 12 universities in Medicon Valley are further-
more united in the Øresund University alliance.
This alliance increases co-operation between the
universities within education and research. The
alliance also enhances collaboration with busi-
ness and industry in the region as well as with
the public authorities. In this way the best ele-
ments of the two countries’ university systems
can stimulate and spur each other towards be-
coming even better universities.
HIGH MOBILITY
Workforce mobility between the Danish and
Swedish parts of Medicon Valley is high – this is
mostly thanks to the Øresund Bridge that con-
nects the two countries. Nearly 20,000 commu-
ters a day cross the border. A major advantage
of this integrated labour market is that compa-
nies can draw on the strengths of both Swedish
and Danish talents. As a result, more and more
companies are choosing to set up their Scandi-
navian head office or service centre in the
region ensuring instant access to two Scandi-
navian markets and languages. Between 2002
and 2007, 70 headquarters have been placed in
the region, most of them in Copenhagen.
LANGUAGE SKILLS
There are very few language barriers in Medicon
Valley. Almost 90% of the population in Denmark
and Sweden speak English, and many people also
speak German, Spanish or French. According to
the IMD World Competitiveness Yearbook 2007,
the two countries are in the top ten with regards
to language skills. The Danish and Swedish
languages are closely related and readily under-
stood on either side of the border.
ACADEMIC RESOURCES
Within Scandinavia there is a very strong em-
phasis on education. Public spending on education,
as a percentage of GDP, is among the highest
in the world (IMD, World Competitiveness Year-
book, 2007). Subsequently, a continuous supply
of qualifi ed young people is ensured by the regi-
on’s 12 universities of which 5 offer life science
educations.
The two main contributors to life science edu-
cations in Medicon Valley are the University of
Copenhagen, founded in 1470, and Lund Univer-
sity, founded in 1666. These two institutions
account for more than 90% of the life science
related students in Scandinavia. These two uni-
versities are also the two largest in Scandinavia
in numbers of students and researchers.
Percentage of population speaking English
Source: Eurobarometer, European Commission, February 2006
Page 19 | Chapter 4 | Access to Talent
Medicon Valley Universities
• 150,000 students attend the Medicon
Valley universities
• 45,000 students are engaged in life
science related educations
• 2,600 life science PhD students
are enrolled at the universities of
Copenhagen and Lund
• 3,500 scientists are engaged in the
public life science research
�����������������������������������������������������������������������������������������������������������������������������������
HB-Medical produces, packs, repacks and fills up for pharmaceutical and biotech companies.
HB-Medical packs and distributes for clinical trials
HB-Medical offers pharmaceutical consulting services
HB-Medical has been approved under section 39 by the Danish Medicines Agency and is authorized by the Danish Veterinary and Food Administration
• Production/packing/repacking• Storage and distribution of study medicine• Storage room with refrigerating facilities• GDP / GMP• Consulting business
Capio Diagnostik a.s.Nygaardsvej 32 DK-2100 Copenhagen O Denmark
www.capiodiagnostik.com
Tel. +45 3374 3000 Fax +45 3374 3030
E-mail: [email protected]
GLP-certified and FDA compliant Laboratory
• Method transfer & method development
• Method validation
• Esoteric tests
• ELISA, RIA, Molecular Biology
����������������
75ye
ars
for h
ealth
Access to Capital
Page 23 | Chapter 5 | Access to Capital
Venture capital, stock issues and license agree-
ments are all well-known possibilities for fi nan-
cing research company development in Medicon
Valley – given it is a region where companies
historically have succeeded in attracting very
large amounts of capital. The track record for
Medicon Valley is extensive and includes the suc-
cess story of the biotech company Genmab,
which had the largest European private offe-
ring in 2000 and the largest deal worldwide be-
tween biotech and big pharma in 2006.
The high levels of investor attraction to Medicon
Valley companies can mainly be explained by
the fact that the regions well-driven biotech
companies provide a stimulating fl ow of news
based on their sound portfolio of new products.
The intelligent and very active local capital mar-
ket also seems to be of vital importance for the
major international investors in Medicon Valley.
LOCAL INVESTORS
Since the 1990s, the venture capital commu-
nity of Medicon Valley has developed rapidly.
Among the prominent local investors are Novo
A/S, BankInvest, Scandinavian Life Science Ven-
ture and Nordic Biotech. They are all dedicated
biotech investors and in 2007, they had a total
of EUR 1 billion funds under management and
have made more than 120 biotech/life science
investments in their portfolio – local as well as
international.
One of the most important initiatives on the
local investor scene is Sunstone Capital. Sun-
stone Capital was founded in 2007 with more
than EUR 300 million in funds under management.
With a dedicated team of experienced invest-
ment managers, Sunstone Capital focuses on
both developed and developing privately-owned
biotech companies, as well as start-up companies.
Novo Nordisk Foundation has a pre-seed fund
to provide fi nancial, managerial and strategic
support to early stage life science projects.
The funding is given as grants with no claims for
payback or ownership of projects. However, the
pre-seed capital market is managed primarily
by the incubators and innovation environments,
which in most cases are located in connection
to science parks and/or universities.
Novo Nordisk Foundation also manages a seed
fund to support more advanced projects and
initiatives not yet at a stage to be supported
by Novo A/S’s existing venture activities or by
other international investors. The seed fund
operates on commercial terms, i.e. support is
given to projects and companies in exchange
for ownership or other rights relating to the
companies/projects.
”As a both local and international player we have observed a very impressive de-velopment in the local biotech companies – product pipelines have been strengthened, more seasoned and international manage-ment engaged and several companies have taken the transition from private to public.”Søren CarlsenManaging PartnerNovo A/S (Bagsværd, Denmark)
A Venture Capital Adventure
In 2006, the biotech SMEs in Medicon Valley
out-performed their European counter-
parts in attracting venture capital. A total
of EUR 710 million was invested in the region
(Nature Biotechnology, Dec. 2006 and Medi-
con Valley Alliance, 2007).
been among others, 3i, Atlas Ventures, Advent
Venture Partners and Merlin Bioscience.
Nordic Venture Summit is another major event
where national and international investors every
year spend their time in Copenhagen to look for
new investment candidates. With great oppor-
tunities for making business presentations and
meetings, Nordic Venture Summit usually attracts
several hundred executives from biotech, ITC and
the investor community.
LOOKING AHEAD
Companies in Medicon Valley have continued to
be highly attractive for the national and inter-
national investors and have continued to pros-
per. The business environment is characte-
rised by a number of factors which have been
and will remain crucial for development – these
include: great R&D news fl ow; a workforce that
is among the most talented globally; and exit
opportunities which seem to rise even higher as
the biotech companies now market their produ-
cts successfully. Based on such assumptions,
the future looks bright for those engaged in life
science activities in Medicon Valley.
International Investors in Medicon Valley
International investors which have invested
in Medicon Valley biotech companies include
among others, Atlas Ventures (US/UK), Index
Ventures (CH), Global Life Science Ventures
(D/CH), AltaPartners (US), Forbion Capital
Partners(NL), Essex Woodlands Health Ven-
tures (US) and NBGI Venture (UK).
”Given the strong science, industrial base and success
stories, we believe there could be many potentially interes-
ting investment opportunities
in Medicon Valley.”Patrick Lee
General Partner Advent Venture Partners (UK)
Guide to Medicon Valley Investors
The numerous pre-seed, seed and venture
capital investors in Medicon Valley are shown
in the Medicon Valley Financing Guide. The
publication provides information on how and
where to attract venture capital, inclu-
ding profi les and contact information on
75 national and international investors. Get
more information at www.mva.org.
Page 24 | Chapter 5 | Access to Capital
INTERNATIONAL INVESTORS
PRESENT IN MEDICON VALLEY
Medicon Valley has experienced remarkable atten-
tion from international investors. In 2006, every
second investor involved in fi nancing rounds in
Medicon Valley biotech companies was from the
international scene. The international investor
community regards Medicon Valley companies
as a very appealing prospect, due to their world
class research, effi ciency and high performan-
ce and also the fact that they are placed in one
of the leading life science clusters in the world
in terms of converting science into patents and
patents into products (Ernst & Young, Beyond
Borders, 2006). Moreover, the presence of phar-
maceutical companies in Medicon Valley for almost
a century means that substantial know-how on
drug development has been transferred into the
local biotech companies. This local know-how
has been one of the key drivers for the late
stage companies’ success in attracting major
international investments.
The international investor awareness of Medi-
con Valley companies seems to be even higher
following the international exposure of the break-
through deals of Genmab and Bavarian Nordic.
As mentioned earlier, these two deals account
for a potential USD 2.1 billion (Genmab, 2006)
and USD 1.6 billion (Bavarian Nordic, 2007).
Another success story is BioInvent, who in 2007
entered in collaboration with Genentech for a
potential 190 million USD.
Several biotech and medtech companies have
made successful IPOs. During 2006-07, Curalogic
Exiqon and LifeCycle Pharma consolidated their
businesses by entering the Nordic Stock Ex-
change OMX, and CellaVision, Genovis and Hansa
Medical were publicly listed on the OMX First North.
INTERNATIONAL EXPOSURE
OF LOCAL COMPANIES
Various activities raise the exposure of Medi-
con Valley companies towards international in-
vestors. The Strictly Financing Award is the
annual investor fl agship event in Medicon Valley,
where a number of its biotech and medtech
companies are nominated to give business pre-
sentations towards a panel of large internatio-
nal investors. The panel decides which company
earns the title as the Best Biotech Company
in Medicon Valley. Participating investors have
The high numbers of life science companies in
Medicon Valley has led to the development of an
effi cient support structure holding a broad range
of life science related service companies and
network organisations. Patent and business at-
torneys, management consultants, investors,
and recruitment companies often have estab-
lishments close to incubators and science parks.
The large fl ow of products in development in
Medicon Valley requires, among other things,
preclinical and clinical research support. Medicon
Valley’s many CROs, CMOs and 11 university hos-
pitals help provide this.
TECH TRANSFER ORGANISATIONS
AND INCUBATORS
The universities and main hospitals have Tech-
nology Transfer Organisations (TTOs), which can
assist with issues around IPRs, out-licensing
or company start-up. Since 2000, Danish uni-
versities have taken ownership of inventions
performed by their researchers, while Swedish
university employees still rely on the “Teacher’s
Exempt”, meaning they are private owners of
their inventions and can choose whether to use
the services of a TTO.
As from 2007, all the technology transfer units
at the Copenhagen-area hospitals have mer-
ged into one TTO placed at the State University
Hospital. At all major hospitals, so-called inno-
vation ambassadors secure an easy access to
the relevant expertise and subsequent coordi-
nation of all the commercialisation resources in
the system in order to secure a steady fl ow of
new business opportunities. The merger of the
three life science universities in Copenhagen
into one has also meant a combined and more
effi cient university technology transfer unit.
In Skåne, the commercialisation of research is
facilitated through a number of collaborating
organisations, including Lund University Inno-
vation System (LUIS) and Innovationsbron Syd,
which is active via Forskarpatent i Syd, Teknopol
and several incubators. It is also worth mentio-
ning Lund Bioscience, which is a new life science
investment fund started in 2007.
Lund Bioincubator at BMC, which welcomed the
fi rst companies in 2007, offers advanced la-
boratory premises for carrying out proof-of-
concept studies. The bioincubator supports
selected companies for up to 3 years through
subsidized rent of the facilities in addition to
offering business development services, educa-
tion and access to various networks. In 2009,
Copenhagen Bio Science Park (COBIS) will open
in central Copenhagen creating a unique envi-
ronment for fostering new biotech companies
at international level. COBIS will offer state-
of-the-art facilities as well as a wide range of
business development services.
Support Structure
”The excellent science parks and incubators in Medicon Valley provide high quality growth conditions with access
to professional networks, labs and services.”Charlotte Ahlgren
Managing DirectorMedeon Science Park (Malmö, Sweden)
Page 26 | Chapter 6 | Support Structure
FULL SERVICE SCIENCE
Medicon Valley hosts six science parks with a
signifi cant focus on life science and another six
incubators. Both science parks and incubators
are situated in close proximity to universities
and other hi-tech environments. They are an
important element in stimulating co-operation
between universities, industry and venture ca-
pital providers. The science parks in Medicon
Valley offer a wide range of services, including
administrative and fi nancial services from seed
capital to venture capital, legal advice and coun-
selling in relation to establishment, networking,
patent applications, marketing, licenses, capital
input etc.
HIGH QUALITY AND COST
EFFECTIVE CLINICAL TRIALS
Denmark and Sweden have long been known for
the high quality of clinical trials, with Good Clini-
cal Practice implemented very early. The willing-
ness of both sets of populations to participate
in clinical trials is high, and this is due to the
focus on safety for test persons, the physicians’
obligation to give thorough information and the
high trust in companies conducting the tests.
This means that the number of drop outs is
limited. Patient organisations are positive to
clinical trials, and may prove helpful in contac-
ting potential study participants or distributing
information about studies.
Compared to the US, the cost of conducting
clinical trials is substantially lower in both Den-
mark and Sweden. One of the reasons for this is
that volunteers who participate in the trials are
remunerated with only a token payment.
Science Parks
• Scion-DTU
(www.sciondtu.dk)
• Symbion Science Park
(www.symbion.dk)
• CAT Science Park
(www.catscience.dk)
• Ideon Science Park
(www.ideon.se)
• Medeon Science Park
(www.medeon.se)
• Krinova Science Park
(www.krinova.se)
Incubators
• DTU Innovation
(www.dtu-innovation.dk)
• Cat-Symbion Innovation
(www.catsymbioninnovation.dk)
• Teknologisk Innovation
(www.tekinno.dk)
• Ideon Innovation
(www.ideoninnovation.se)
• Medeon Incubator
(www.medeon.se)
• Lund BioIncubator
(www.lundbioinkubator.se)
”The biomedical infrastructure here is completely solid – with excel-lent universities, hospitals and clinical research support. We have a very powerful platform for rapid drug development.”Lisa DrakemanPresident and Chief Executive Offi cerGenmab (Copenhagen, Denmark)
Page 27 | Chapter 6 | Support Structure
ceutical R&D based manufacturers and the fl ora
of small and medium sized biotech companies.
Already, Medicon Valley is at the forefront of
developing personalised medicine – and this is
set to grow.
REGISTRATION AND CERTIFICATION
OF MEDICINES AND MEDICAL DEVICES
The regulatory authorities have a very good
reputation and are in the top three as reporters
in EU for mutual recognition throughout Europe.
Non-European companies also frequently use
the Scandinavian countries for performing cli-
nical trials and registrations. For medical de-
vices, there are Notifi ed Bodies, which can be
contracted to perform certifi cation for type II
and III devices.
CONTRACT RESEARCH AND
MANUFACTURING ORGANISATIONS
OF A HIGH STANDARD
Both domestic and international contract re-
search organisations (CROs) are represented
in Medicon Valley, including the headquarters
of Sweden’s and Denmark’s largest CROs. The
CROs are well established and renowned for their
high standards of quality. They offer a variety
of services and many are capable of conducting
complete preclinical and clinical projects from
start to fi nish, naturally carried out in accordance
with guidelines for both Good Laboratory Prac-
tice (cGLP) and Good Clinical Practice (cGCP).
A number of contract manufacturing organi-
sations (CMOs) are also present, offering effi -
cient manufacturing in accordance with Good
Manufacturing Practice (cGMP) standards.
A COMPREHENSIVE POPULATION
REGISTRATION SYSTEM
The two countries’ social health care systems
provide further benefi ts for clinical research. All
Danish and Swedish citizens have free and equal
access to healthcare, and medical and genetic
data are tracked from birth to death through the
central population register. This ensures that
all population segments are represented in samp-
ling. The two countries’ databases are also among
the most comprehensive, sophisticated and well-
maintained in the world.
This applies to the Danish Cancer Register, which
has existed since 1943 and the Swedish Cancer
Register which dates back to 1957. The regi-
sters contain data on the occurrence of cancer
and other diseases subjected to notifi cation.
The permission to use these registers and the
notifi cation of diseases is a great advantage
when doing clinical trials, as it makes it possible
to track patients over time and to gain a deeper
insight into their medical history.
Another advantage is the biobanks which enable
important research to be carried out – infor-
mation from biobanks is coupled to national
registries. This is unique for the Nordic coun-
tries.
AN EXCEPTIONAL PLACE TO
DEVELOP PERSONALISED MEDICINE
The concept of personalised medicine – being the
understanding of the molecular basis of health
and disease, and the development of highly tar-
geted and individualised diagnostics and thera-
peutic regimens – will become a reality within the
next decade. This emergence of targeted the-
rapies will generate unique opportunities for all
stakeholders across the entire life science value
chain.
Medicon Valley has a signifi cant advantage in its
effort to make this exciting new concept a rea-
lity. This is due to the region’s long experience
in private public partnerships, the unmatched
infrastructure in combination with the presence
of several diagnostic companies, major pharma-
Page 28 | Chapter 6 | Support Structure
Drug and Device Development Guide
The Drug and Device Development Guide
gives information about the CROs and
regional hospital departments that are
involved in clinical trials. Order the guide at
www.mva.org.
Number of NCE rapporteurships in the centralized procedure in Europe 1995-2004
Medicinal products for human use. Source: NDA Regulatory Science Ltd UK, 2007.
Page 29 | Chapter 6 | Support Structure
Due to its geographical location and connec-
tivity, Medicon Valley is the natural key point of
entry into Scandinavia. It serves as the Scandi-
navian hub and traffi c linkage point between the
region and the Baltic countries. Copenhagen
Airport offers the largest number of direct
intercontinental, European, Scandinavian and
Baltic fl ight connections in Scandinavia. By using
the Metro, you can arrive in the centre of Copen-
hagen a mere 15 minutes later and with the Øre-
A Location in Medicon Valley Ensures:
• Close proximity to a large number of delivery points
• Effi cient modes of transportation that allow distributors to plan logistics fl ows in an effi cient
manner
• New terminals and intermodal transportsystems in place linking air, sea, road and rail transport
• Major full-service logistics providers such as FedEx and DHL, which have placed their Nordic
operations in Copenhagen, providing excellent services and outsourcing opportunities
• Access to a highly effi cient public transportation system
Infrastructuresund train you reach Malmö in about the same
time span.
MEDICON VALLEY – A NEW SCANDINAVIAN BASE
The Øresund Bridge between Copenhagen and
Malmö has expanded the highway network and
linked Denmark and Sweden more effectively in
and around Medicon Valley. The travel distance
between the two cities has been reduced to just
30 minutes.
Page 32 | Chapter 7 | Infrastructure
Furthermore, Øresund trains crossing the bridge
every 20 minutes effi ciently link the cities and
towns of Denmark and Sweden. At the northern
end of Øresund, ferries link Helsingborg and
Helsingør every 15 minutes.
The Copenhagen-Malmö Port, which has a total
cargo turnover of 15.2 million tons per annum,
has scheduled routes to many Nordic and Baltic
Sea harbours – often with daily services.
Copenhagen Airport is the largest cargo airport
in northern Europe, handling over 350,000 tons
of cargo every year, and with direct fl ights to
more than thirty cargo destinations.
Another important airport is Malmö Airport,
which is located just outside the city with a
short trip of only 15 minutes to Lund and 60
minutes to Copenhagen.
Page 33 | Chapter 7 | Infrastructure
The Øresund region is an area that refl ects the
modern age with eastern Denmark and southern
Sweden complementing one another in a commu-
nity without frontiers.
ADVANCED LIFESTYLE
Medicon Valley offers an advanced lifestyle that
is highly attractive for creative professionals
and companies wanting to lead the marketplace
through innovation. The work-life balance, de-
signed for the benefi t of society, technological
superiority and a unique green environment are
all aspects of the lifestyle.
Inhabitants in Medicon Valley are among the world’s
most affl uent in both monetary and quality of
life terms. Denmark and Sweden are in the top
10 of the world’s best countries to live in, accor-
ding to The Economist. Copenhagen has recei-
ved very good rankings in international surveys
focusing on quality of life as well as happiness.
A PERFECT BALANCE
In Medicon Valley, combining work and family life
is a different experience. It is a pleasantly posi-
tive surprise for many – and highly appealing to
professionals. In Medicon Valley, you are able to
have a career that is on track as well as a ful-
fi lling family life. Workplaces prioritise fl exible
working hours and cater for the family life of
their employees without compromising produc-
tivity. Free schools and health services, easy
access to childcare and a safe and a healthy
environment are just some of the benefi ts you
can enjoy. Not surprisingly, we hear business
professionals refer to the region as “the busi-
ness world’s best kept secret”.
VIBRANT CULTURE
On top of all this, Medicon Valley also offers
places such as Copenhagen and Malmö – cities
that are culturally sophisticated, vibrant, clean
and safe. Both cities are designed to accommo-
date bicyclists and pedestrians – one reason the
region’s motor traffi c congestion is relatively low.
CLOSE TO NATURE
Medicon Valley is a diverse and fascinating re-
gion from many perspectives. The region as a
whole is bordered by wonderful sandy beaches
and you are never far from green forests and the
countryside. Equally, spending time in Copenhagen
and Malmö will also give you a taste of modern
urban life, which is greener and less polluted.
The waterfront on both sides of Øresund is so
clean that it is possible to take a swim in the
open-air baths or the inner harbour beaches.
Moreover, the coast of Øresund offers un-
limited access to several beaches and marinas.
You can easily go by train, car or bike to beaches
and forests – all within only a short distance !
Quality of Life
Page 34 | Chapter 8 | Quality of Life
Why Medicon Valley ?
• The region has high job quality and happy
employees: Scandinavian colleagues are
teamplayers, fl exible to work with, innova-
tive and productive. Scandinavian work-
places also show a great deal of respect
for family life.
• The quality of living is high in the region:
A positive balance between family and
work life, with no need to spend hours in
traffi c jams – public services are fast and
effi cient.
• The region is a safe and sound place for
families offering an ideal environment to
raise children – personal safety is high
and pollution is low.
• There is high satisfaction with recreatio-
nal activities – including entertainment,
restaurants, music, arts, theatres, and
sports facilities.
”Many people are attracted to the region because of the large and
varied labour market and also because it offers a very comfortable and
enjoyable life style.”Cristina Glad
Executive Vice PresidentBioInvent (Lund, Sweden)
Page 35 | Chapter 8 | Quality of Life
Medicon Valley Alliance (www.mva.org) is the cluster organisation for
Medicon Valley. We facilitate network and knowledge sharing activities
between private and public players and manage cluster development
projects. We have a strong international network and are involved in
cluster-to-cluster collaborations with bioregions worldwide. Our 270 mem-
bers are made up of life science companies, universities, hospitals and
service providers in Medicon Valley.
Copenhagen Capacity (www.copcap.com) is the offi cial investment pro-
motion agency for Greater Copenhagen, the Capital Region of Denmark
and part of the Øresund Region. Copenhagen Capacity is publicly funded
and provides free assistance to foreign companies interested in estab-
lishing activities or contacts in Medicon Valley, especially in the Danish
part of Medicon Valley.
Region Skåne, Department of Economic Development & Innovation
(www.skane.com/invest) is the official organisation responsible for
investment promotion for Skåne, Sweden’s southernmost region and
part of the Øresund Region. Region Skåne is publicly funded and provides
free assistance to foreign companies interested in establishing activities
or contacts in Medicon Valley, especially in the Swedish part of Medicon
Valley.
Page 39 | Chapter 9 | Point of Entries
Point of Entries
© Copenhagen Capacity | Region Skåne | Kiberg & Gormsen
Get more information !
Please feel free to contact us with your questions about Medicon Valley. We are here to help.
Medicon Valley AllianceDenmark
Arne Jacobsens Allé 15, 2.
DK-2300 Copenhagen S
Tel: +45 35 32 41 50
Fax: +45 35 32 41 59
E-mail: [email protected]
Web: www.mva.org
Medicon Valley AllianceSweden
Øresundshuset
Box 117
SE-221 00 Lund
Visit: Østra Vallgatan 14, Lund
Tel: +46 46 222 16 80
Fax: +46 46 222 09 84
E-mail: [email protected]
Web: www.mva.org
Copenhagen Capacity
Gammel Kongevej 1
DK-1610 Copenhagen V
Denmark
Tel: +45 33 22 02 22
Fax: +45 33 22 02 11
E-mail: [email protected]
Web: www.copcap.com
Region Skåne
Department of Economic
Development & Innovation
Stortorget 9
SE-211 22 Malmö
Sweden
Tel: +46 40 623 9748
Fax: +46 40 623 9753
E-mail: [email protected]
Web: www.skane.com/invest
Get more information atwww.mediconvalley.com